none25noneBringhen S; Larocca A; Rossi D; Cavalli M; Genuardi M; Ria R; Gentili S; Patriarca F; Nozzoli C; Levi A; Guglielmelli T; Benevolo G; Callea V; Rizzo V; Cangialosi C; Musto P; De Rosa L; Liberati AM; Grasso M; Falcone AP; Evangelista A; Cavo M; Gaidano G; Boccadoro M; Palumbo A.Bringhen S; Larocca A; Rossi D; Cavalli M; Genuardi M; Ria R; Gentili S; Patriarca F; Nozzoli C; Levi A; Guglielmelli T; Benevolo G; Callea V; Rizzo V; Cangialosi C; Musto P; De Rosa L; Liberati AM; Grasso M; Falcone AP; Evangelista A; Cavo M; Gaidano G; Boccadoro M; Palumbo A
Maria Teresa Petrucci, Paola Finsinger, Marta Chisini, Fabiana GentiliniDepartment of Cellular Biote...
目的:系统评价硼替佐米在不同剂量下治疗多发性骨髓瘤的疗效与安全性。方法检索PubMed、Cochrane Library、EmBase、中国生物医学文献( CBM)、中国知网( CNKI)、万方和维普...
目的 探讨硼替佐米周用药化疗方案治疗初诊多发性骨髓瘤(MM)的效果及安全性.方法 回顾性选取2012年11月至2014年8月在北京大学血液病研究所入组接受治疗的初诊MM患者40例,所有患者均采用PAD...
In a recent phase 3 trial, bortezomib-melphalan-prednisone-thalidomide followed by maintenance treat...
In a recent phase 3 trial, bortezomibmelphalan-prednisone-thalidomide followed by maintenance treatm...
In a recent phase 3 trial, bortezomib-melphalan-prednisone-thalidomide followed by maintenance treat...
none22noneMorabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D;...
We conducted a single-center, prospective clinical trial in which a subcutaneous bortezomib (Bor) re...
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies...
Introduction: Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow mic...
Introduction: Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow mic...
Renal impairment (RI) is a severe complication throughout the course of multiple myeloma (MM). Borte...
Renal impairment (RI) is a severe complication throughout the course of multiple myeloma (MM). Borte...
Bortezomib, a first generation proteasome inhibitor, is used in both newly diagnosed and relapsed my...
Despite intensive therapy, multiple myeloma (MM) remains an incurable disease, and novel treatment a...
Maria Teresa Petrucci, Paola Finsinger, Marta Chisini, Fabiana GentiliniDepartment of Cellular Biote...
目的:系统评价硼替佐米在不同剂量下治疗多发性骨髓瘤的疗效与安全性。方法检索PubMed、Cochrane Library、EmBase、中国生物医学文献( CBM)、中国知网( CNKI)、万方和维普...
目的 探讨硼替佐米周用药化疗方案治疗初诊多发性骨髓瘤(MM)的效果及安全性.方法 回顾性选取2012年11月至2014年8月在北京大学血液病研究所入组接受治疗的初诊MM患者40例,所有患者均采用PAD...
In a recent phase 3 trial, bortezomib-melphalan-prednisone-thalidomide followed by maintenance treat...
In a recent phase 3 trial, bortezomibmelphalan-prednisone-thalidomide followed by maintenance treatm...
In a recent phase 3 trial, bortezomib-melphalan-prednisone-thalidomide followed by maintenance treat...
none22noneMorabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D;...
We conducted a single-center, prospective clinical trial in which a subcutaneous bortezomib (Bor) re...
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies...
Introduction: Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow mic...
Introduction: Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow mic...
Renal impairment (RI) is a severe complication throughout the course of multiple myeloma (MM). Borte...
Renal impairment (RI) is a severe complication throughout the course of multiple myeloma (MM). Borte...
Bortezomib, a first generation proteasome inhibitor, is used in both newly diagnosed and relapsed my...
Despite intensive therapy, multiple myeloma (MM) remains an incurable disease, and novel treatment a...
Maria Teresa Petrucci, Paola Finsinger, Marta Chisini, Fabiana GentiliniDepartment of Cellular Biote...
目的:系统评价硼替佐米在不同剂量下治疗多发性骨髓瘤的疗效与安全性。方法检索PubMed、Cochrane Library、EmBase、中国生物医学文献( CBM)、中国知网( CNKI)、万方和维普...
目的 探讨硼替佐米周用药化疗方案治疗初诊多发性骨髓瘤(MM)的效果及安全性.方法 回顾性选取2012年11月至2014年8月在北京大学血液病研究所入组接受治疗的初诊MM患者40例,所有患者均采用PAD...